Nabriva Therapeutics Ag Stock Revenue

Nabriva Therapeutics AG fundamentals help investors to digest information that contributes to Nabriva Therapeutics' financial success or failures. It also enables traders to predict the movement of Nabriva Stock. The fundamental analysis module provides a way to measure Nabriva Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nabriva Therapeutics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Nabriva Therapeutics AG Company Revenue Analysis

Nabriva Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Current Nabriva Therapeutics Revenue

    
  35.67 M  
Most of Nabriva Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nabriva Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, Nabriva Therapeutics AG reported 35.67 M of revenue. This is 99.53% lower than that of the Pharmaceuticals sector and 95.2% lower than that of the Health Care industry. The revenue for all United States stocks is 99.62% higher than that of the company.

Nabriva Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nabriva Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nabriva Therapeutics could also be used in its relative valuation, which is a method of valuing Nabriva Therapeutics by comparing valuation metrics of similar companies.
Nabriva Therapeutics is currently under evaluation in revenue category among its peers.

Nabriva Fundamentals

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Consideration for investing in Nabriva Stock

If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences